This phase III trial is comparing two drugs (APL-2 and Eculizumab) for the treatment of the rare blood disease Paroxysmal Nocturnal Hemoglobinuria (PNH).
This trial is treating patients with Paroxysmal Nocturnal Hemoglobinuria (PNH).
This is a systemic therapy trial.
You may be able to join this trial if:
- You are currently receiving treatment for your cancer.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase III, Randomized, Multi-Center, Open-Label, Active-Comparator Controlled Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Apellis Pharmaceuticals, Inc.
Not Recruiting Hospitals Read More